202 related articles for article (PubMed ID: 34625582)
1. BRAF mutations may identify a clinically distinct subset of glioblastoma.
McNulty SN; Schwetye KE; Ferguson C; Storer CE; Ansstas G; Kim AH; Gutmann DH; Rubin JB; Head RD; Dahiya S
Sci Rep; 2021 Oct; 11(1):19999. PubMed ID: 34625582
[TBL] [Abstract][Full Text] [Related]
2. BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity.
Nakajima N; Nobusawa S; Nakata S; Nakada M; Yamazaki T; Matsumura N; Harada K; Matsuda H; Funata N; Nagai S; Nakamura H; Sasaki A; Akimoto J; Hirato J; Yokoo H
Brain Pathol; 2018 Sep; 28(5):663-673. PubMed ID: 29105198
[TBL] [Abstract][Full Text] [Related]
3. Cerebellar glioblastoma: a clinical series with contemporary molecular analysis.
Hong B; Banan R; Christians A; Nakamura M; Lalk M; Lehmann U; Hartmann C; Krauss JK
Acta Neurochir (Wien); 2018 Nov; 160(11):2237-2248. PubMed ID: 30203362
[TBL] [Abstract][Full Text] [Related]
4. Genomic landscape of gliosarcoma: distinguishing features and targetable alterations.
Zaki MM; Mashouf LA; Woodward E; Langat P; Gupta S; Dunn IF; Wen PY; Nahed BV; Bi WL
Sci Rep; 2021 Sep; 11(1):18009. PubMed ID: 34504233
[TBL] [Abstract][Full Text] [Related]
5. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.
Kleinschmidt-DeMasters BK; Aisner DL; Foreman NK
Am J Surg Pathol; 2015 Apr; 39(4):528-40. PubMed ID: 25581727
[TBL] [Abstract][Full Text] [Related]
6. The Significance of
Prieto R; Barrios L; Ebrat-Mancilla E; MartÃn P; Tejerina E
Int J Surg Pathol; 2024 Jun; 32(4):649-666. PubMed ID: 37743598
[TBL] [Abstract][Full Text] [Related]
7. Molecular Characterization of Adult Tumors Diagnosed as Cerebellar Glioblastomas Identifies Subgroups Associated With Prognosis.
Picart T; Poncet D; Barritault M; Bauchet L; Zouaoui S; Guyotat J; Gabut M; Fina F; Honnorat J; Figarella-Branger D; Pallud J; Ducray F; Meyronet D; ;
Am J Surg Pathol; 2023 Jan; 47(1):131-144. PubMed ID: 36418240
[TBL] [Abstract][Full Text] [Related]
8. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers.
Korshunov A; Ryzhova M; Hovestadt V; Bender S; Sturm D; Capper D; Meyer J; Schrimpf D; Kool M; Northcott PA; Zheludkova O; Milde T; Witt O; Kulozik AE; Reifenberger G; Jabado N; Perry A; Lichter P; von Deimling A; Pfister SM; Jones DT
Acta Neuropathol; 2015 May; 129(5):669-78. PubMed ID: 25752754
[TBL] [Abstract][Full Text] [Related]
9. EGFR amplification is a real independent prognostic impact factor between young adults and adults over 45yo with wild-type glioblastoma?
Armocida D; Pesce A; Frati A; Santoro A; Salvati M
J Neurooncol; 2020 Jan; 146(2):275-284. PubMed ID: 31889239
[TBL] [Abstract][Full Text] [Related]
10. Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma.
Matsumura N; Nakajima N; Yamazaki T; Nagano T; Kagoshima K; Nobusawa S; Ikota H; Yokoo H
Neuropathology; 2017 Feb; 37(1):58-63. PubMed ID: 27302309
[TBL] [Abstract][Full Text] [Related]
11. The post-surgical era of GBM: How molecular biology has impacted on our clinical management. A review.
Monticelli M; Zeppa P; Zenga F; Altieri R; Mammi M; Bertero L; Castellano I; Cassoni P; Melcarne A; La Rocca G; Sabatino G; Ducati A; Garbossa D
Clin Neurol Neurosurg; 2018 Jul; 170():120-126. PubMed ID: 29777944
[TBL] [Abstract][Full Text] [Related]
12. Adult classical glioblastoma with a BRAF V600E mutation.
Takahashi Y; Akahane T; Sawada T; Ikeda H; Tempaku A; Yamauchi S; Nishihara H; Tanaka S; Nitta K; Ide W; Hashimoto I; Kamada H
World J Surg Oncol; 2015 Mar; 13():100. PubMed ID: 25885250
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of BRAF Mutation in Glioblastoma.
Sohail A; Virani QU; Aziz HF; Shamim MS
J Pak Med Assoc; 2024 Jan; 74(1):185-186. PubMed ID: 38219188
[TBL] [Abstract][Full Text] [Related]
14. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes.
Newcomb EW; Cohen H; Lee SR; Bhalla SK; Bloom J; Hayes RL; Miller DC
Brain Pathol; 1998 Oct; 8(4):655-67. PubMed ID: 9804374
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological and genetic association between epithelioid glioblastoma and pleomorphic xanthoastrocytoma.
Furuta T; Miyoshi H; Komaki S; Arakawa F; Morioka M; Ohshima K; Nakada M; Sugita Y
Neuropathology; 2018 Jun; 38(3):218-227. PubMed ID: 29532523
[TBL] [Abstract][Full Text] [Related]
16. Epithelioid GBMs show a high percentage of BRAF V600E mutation.
Kleinschmidt-DeMasters BK; Aisner DL; Birks DK; Foreman NK
Am J Surg Pathol; 2013 May; 37(5):685-98. PubMed ID: 23552385
[TBL] [Abstract][Full Text] [Related]
17. Epithelioid glioblastoma with microglia features: potential for novel therapy.
Nakagomi N; Sakamoto D; Hirose T; Takagi T; Murase M; Nakagomi T; Yoshimura S; Hirota S
Brain Pathol; 2020 Nov; 30(6):1119-1133. PubMed ID: 32687679
[TBL] [Abstract][Full Text] [Related]
18. Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation.
Tanaka S; Nakada M; Nobusawa S; Suzuki SO; Sabit H; Miyashita K; Hayashi Y
Brain Tumor Pathol; 2014 Jul; 31(3):172-6. PubMed ID: 24894018
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG
Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224
[TBL] [Abstract][Full Text] [Related]
20. Predicting BRAF V600E mutation in glioblastoma: utility of radiographic features.
Natsumeda M; Chang M; Gabdulkhaev R; Takahashi H; Tsukamoto Y; Kanemaru Y; Okada M; Oishi M; Okamoto K; Rodriguez FJ; Kakita A; Fujii Y; Schreck KC
Brain Tumor Pathol; 2021 Jul; 38(3):228-233. PubMed ID: 34216310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
